Annotated abstract

Risk of secondary T-cell malignancy after CAR T-cell therapy

dtb · 2025-09-29 · canonical JSON source

3 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

Abstract Overview of: European Medicines Agency. CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin [online], 2024. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024[Accessed 22 May 2025].